Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission

Prior treatment

• 3.Major surgery within the past 4 weeks (excluding diagnostic surgical procedures);
• 4.History of or concurrent other malignant tumors (excluding well-controlled non-melanoma basal cell carcinoma of the skin, breast/cervical carcinoma in situ, and other malignancies well controlled without treatment for more than five years);
• 9.Participation in another ongoing clinical trial, or enrollment in any other drug clinical trial within the past 1 month;
• 11.Patients who are unable to understand the trial protocol, adhere to medication instructions, or refuse to sign the informed consent form;

Other illness

• 2.Known hypersensitivity to any drugs in the conditioning regimen or their excipients;
• 5\. Uncontrolled systemic diseases (such as uncontrolled hypertension, diabetes mellitus, etc.);
• 7.Uncontrolled ongoing infection, or patients requiring mechanical ventilation or with hemodynamic instability;
• 8.Patients with psychiatric disorders or other medical conditions who are unable to comply with study treatment and monitoring requirements;

Lab values

• 6.Active hepatitis B or hepatitis C infection:（Hepatitis B virus surface antigen positive, hepatitis B core antibody positive with HBV-DNA level exceeding 1×103 copies/mL;Hepatitis C virus RNA level exceeding 1×10 3 copies/mL）;

Other

• 1.Refractory/relapsed AML;
• 10.Pregnant or lactating females, and patients who refuse to use effective contraception during the study period;
• 12.Patients deemed ineligible for enrollment by the investigator.

• 1.Aged from 18 to 60 years inclusive, with no restriction on gender;
• 2.Patients diagnosed with acute myeloid leukemia (AML, excluding acute promyelocytic leukemia, APL) by bone marrow morphological, immunological and genetic examinations according to the 2022 World Health Organization (WHO) classification, who have achieved first complete remission (CR1) after induction therapy;
• 3.Meeting any of the following criteria upon clinical evaluation:
  • AML classified as intermediate or adverse genetic risk according to the 2022 ELN genetic risk stratification;
  • AML with positive measurable residual disease (MRD) before transplantation;
• 4.Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0-2;
• 5.Estimated survival time more than 6 months;
• 6.Meeting the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT), and having an eligible hematopoietic stem cell donor with qualified physical examination, including HLA-matched sibling donor, unrelated donor (high-resolution HLA 9-10/10 matched) or haploidentical related donor;
• 7.Adequate major organ function meeting the following criteria:
  • Total bilirubin (TBIL) ≤ 2 times the upper limit of normal (ULN); Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤ 3 × ULN;
  • Serum creatinine (Cr) ≤ 1.5 × ULN, or estimated creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault glomerular filtration formula;
  • Coagulation function meeting the following standards: Prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN (without anticoagulant therapy);
  • Electrocardiogram showing no acute myocardial infarction or severe arrhythmia; Echocardiography with left ventricular ejection fraction (LVEF) ≥ 50%, without significant cardiomegaly, valvular heart disease or congenital heart disease;
  • Pulmonary function tests: FEV1, FVC and DLCO ≥ 60% of predicted value;
• 8.Willing to provide available diagnostic evidence or undergo bone marrow aspiration and biopsy prior to study treatment, and agree to receive regular bone marrow aspiration and biopsy after study treatment;
• 9.Must sign the informed consent form prior to study enrollment, signed by the patient personally or immediate family members. If signature by the patient is deemed detrimental to disease treatment based on clinical condition assessment, the informed consent shall be signed by the legal guardian or immediate family member of the patient.